The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.
|Actual Study Start Date :||July 27, 2020|
|Estimated Primary Completion Date :||October 27, 2022|
|Estimated Study Completion Date :||October 27, 2022|